- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03593369
Assessment of the Evolution of Wound Biomarkers in Venous Leg Ulcers Treated With KLOX Biophotonic System
A Prospective Controlled Randomized Clinical Study Exploring The Evolution Of Wound Biomarkers With TWO Dispensing Schedules Of The KLOX LumiHeal Gel And The KT-L Lamp Versus Standard Of Care In Venous Leg Ulcers
Study Overview
Status
Conditions
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Pisa, Italy, 56126
- Recruiting
- Clinica Dermatologica Azienda Ospedaliero-Universitaria Pisana
-
Contact:
- Valentina Dini, MD
- Email: dott.valentinadini@yahoo.it
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or female 18 to 85 years of age, ambulatory or hospitalized patients;
- Patient agrees to participate in protocol schedule of visits, including follow-up evaluations;
- Patient to be enrolled must be able to adhere to the Standard of Care and to the treatments with the KLOX LumiHeal™ Gel and the KT-L Lamp described in the protocol;
- Patient or an authorised person must be able to read and understand informed consent, and sign or delegate signature of the informed consent form;
- Fitzpatrick skin type I to IV;
- Proven venous leg ulcer, clinically defined and confirmed by duplex, refilling time or venous hypertension;
- Ulcer to be treated must be measurable and with an area between 5 and 100 cm2 inclusively, with a maximum depth of 1 cm and maximum diameter less or equal to 10 cm;
- If applicable, patients (male a female) must be willing to adhere to a medically-accepted birth control method (verified by the Investigator);
- Stable wound surface area with an absolute change in wound area less than 30% as measured at Baseline Visit compared to the Screening Visit.
Exclusion Criteria:
- Venous leg ulcer presents for less than 4 weeks or more than 18 months at Screening;
- The patient has more than one ulcer in the treated leg and the ulcer(s) not being assessed are within 5 cm of the targeted ulcer;
- The ulcer to be treated requires operative debridement or revascularization;
- The ulcer has significant necrotic tissue, as defined by more than 20% of the ulcer area after debridement;
- Major uncontrolled medical disorders such as serious cardiovascular, renal, liver or pulmonary disease, palliative care, or other chronic diseases such as lupus or sickle cell anemia;
- Patient with known moderate to severe anemia;
- Patient with history of malignancy within the wound or patient with prior diagnosis of malignant disease who is less than one year disease-free;
- Patient who has experienced a hip fracture in the past 3 months;
- Patient with known osteomyelitis or active cellulitis;
- Patients who are immunosuppressed or on high dose of chronic steroid use (defined as oral dose of 7.5 mg or more of prednisone daily, or equivalent, for more than 28 days);
- Patient with active wound infection or with systemic infection (the patient is however eligible for re-screening after the active wound infection or the systemic infection has subsided);
- Successful revascularization surgery of the leg with the ulcer to be treated less than 8 weeks prior to Screening;
- Concurrent participation in another clinical trial that involves an investigational drug or device that would interfere with this study, or participation within the past 60 days in another interventional wound healing clinical trial;
- History of radiation therapy to the wound region;
- Pregnancy, or breast feeding;
- Patients with bleeding diathesis;
- Patients on an uncontrolled anti-coagulation therapy;
- The subject has any physical or psychiatric condition that, in the Investigator's opinion, would warrant exclusion from the study or prevent the subject from completing the study;
- Concurrent disease or drugs known to induce severe photosensitivity of the skin, such as porphyria;
- Patient has received biological-based therapy, skin grafts or Negative Pressure Wound Therapy in the ulcer to be treated within last 3 months prior to Baseline.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KLOX BioPhotonic System (single treatment)+SOC
KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered twice weekly in association with SOC (10 patients)
|
KLOX BioPhotonic system (composed of LumiHeal Gel and KT-L Lamp). In this study arm one treatment will be assessed - two visits per week. Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks). |
Experimental: KLOX BioPhotonic System (consecutive treatments)+SOC
KLOX BioPhotonic System (LumiHeal Gel plus KLOX Multi-LED KT-L Lamp) will be administered in two consecutive treatments (twice weekly on the first two weeks then once weekly) in association with SOC (10 patients)
|
In this study arm, two consecutive treatments during the same visit will be evaluated- two visits for the first two weeks, then one visit per week. Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks). |
Active Comparator: Standard of Care
SOC only (5 patients)
|
Standard of Care (SOC) for wound healing will be administered during the treatment and follow-up periods (20 weeks).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of biomarkers expression in biopsies and exudates of the venous leg ulcers.
Time Frame: Up to 20 weeks
|
Comparison of the expression of biomarkers in biopsies and exudates of the venous leg ulcers in the three treatment groups.
|
Up to 20 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events, Serious adverse events, device incidents and compliance.
Time Frame: Up to 20 weeks
|
Number of adverse events, serious adverse events, device incidents and missed treatment visits.
|
Up to 20 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Valentina Dini, MD, Azienda Ospedaliero, Universitaria Pisana
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CL-K1002-P013
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Venous Leg Ulcer
-
Gloucestershire Hospitals NHS Foundation TrustNot yet recruitingLeg Ulcer | Venous Leg Ulcer | Venous Insufficiency of Leg | Venous Ulcer
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
DeRoyal Industries, Inc.Royal College of Surgeons, Ireland; Enterprise Ireland; Tyndall National InstituteCompletedVenous Leg Ulcer | Venous Insufficiency of LegIreland
-
Chang Gung Memorial HospitalRecruitingVenous Leg Ulcer | Venous Insufficiency of Leg | Venous Occlusion | Contrast Media ReactionTaiwan
-
Ortec InternationalCompletedVenous Leg Ulcer | Venous Stasis UlcerUnited States
-
Firstkind LtdTerminatedLeg Ulcer | Venous Leg Ulcer | Venous UlcerCanada
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States, Australia, Germany, Italy, United Kingdom, New Zealand, Ireland
-
W.L.Gore & AssociatesRecruitingVenous Leg Ulcer | Venous Stasis | Venous Stenosis | Venous Occlusion | Venous Ulcer | Venous Thromboses | Venous Disease | Vein Thrombosis | Vein Occlusion | Vein DiseaseUnited States
-
Firstkind LtdCompletedLeg Ulcer | Venous Leg Ulcer | Wound | Wound Leg | Leg Ulcers VenousUnited Kingdom
-
Mansoura UniversityActive, not recruitingVaricose Veins | Venous Insufficiency | Venous Leg Ulcer | Venous RefluxEgypt
Clinical Trials on KLOX BioPhotonic System (single treatment)+SOC
-
KLOX Technologies Inc.CompletedDiabetic Foot UlcersCanada
-
KLOX Technologies Inc.Completed
-
KLOX Technologies Inc.CompletedPressure Ulcers Stage II | Pressure Ulcers Stage IIICanada
-
KLOX Technologies Inc.Completed
-
KLOX Technologies Inc.CompletedSurgical WoundsCanada
-
KLOX Technologies Inc.CompletedDiabetic Foot Ulcer | Venous Leg Ulcer | Pressure Ulcer
-
Mahidol UniversityAlign Technology, Inc.Completed
-
Neurotronic, Inc.Libra MedicalRecruitingAblation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities (NECTAR IV)Hypertension | Diabetes Mellitus, Type 2Georgia
-
Mahidol UniversityITI International Team for Implantology, SwitzerlandCompleted
-
University of Alabama at BirminghamColumbia University; Centre for Infectious Disease Research in ZambiaRecruitingAlcohol-Related Disorders | HIV/AIDS | Mental IllnessZambia